首頁 > 市場調查報告書 > 製藥

感染疾病

市場調查報告書

商品編碼

1122435

傷寒疫苗市場：按疫苗類型、給藥途徑、地區 - 規模、份額、前景和機會分析，2022-2030

Typhoid Fever Vaccines Market, by Vaccine Type, by Route of Administration, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

出版日期: 2022年08月23日 | 出版商:

Coherent Market Insights | 英文 177 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

傷寒是一種由傷寒沙門氏菌引起的細菌感染，會引起長時間發燒、頭痛、噁心、食慾不振、便秘，有時還會出現腹瀉等症狀。細菌通常通過攝入受污染的食物或水通過口腔進入體內，穿透腸壁，並在淋巴組織中繁殖。然後它進入血液並引起菌血症。飲用受污染的水或食用用受污染的水清洗過的食物的人可能會患上傷寒。傷寒主要發生在衛生條件差、沒有乾淨飲用水的地區。傷寒疫苗是一種生物製劑，可以免疫並保護患者免受傷寒的侵害。

目前，世界衛生組織（WHO）推薦以下三種傷寒疫苗。

可注射的傷寒結合疫苗 (TCV) 結合了 Vi 多醣抗原和破傷風類毒素蛋白，已獲准用於 6 個月大的兒童和 45 歲或以下的成人。
用於 2 歲及以上兒童的使用純化 Vi 抗原的可注射非結合多醣疫苗（通常稱為 Vi-PS 疫苗），以及
適用於 6 歲及以上兒童的膠囊劑型口服 Ty21a 減毒活疫苗。

市場動態

政府和其他各種組織增加舉措以提高對傷寒疫苗的認識，以及增加獲得新疫苗的機會，預計將在預測期內推動傷寒疫苗市場的增長。例如，2019 年 2 月，疫苗聯盟 Gavi 與世衛組織、疾病控制和預防中心以及津巴布韋衛生部合作，發起了一場抗擊津巴布韋傷寒疫情的運動。 Gavi，疫苗聯盟是一個公私合作夥伴關係，幫助為世界上一半的兒童接種疫苗以對抗世界上最致命的疾病。該活動的目標是在津巴布韋首都附近的九個地點使用新的傷寒結合疫苗 (TCV) 覆蓋 325,000 人。全世界至少有 1240 萬兒童被歸類為“零劑量”，他們生活在孤獨的社區，無法獲得包括醫療保健在內的許多基本服務。

本研究的主要特點

本報告對全球傷寒疫苗市場進行了深入分析，提供了以 2021 年為基準年的預測期間（2022-2030 年）的市場規模和復合年增長率 (CAGR%)。
解釋不同細分市場的潛在收入機會，並描述該市場具有吸引力的投資建議矩陣。
它還提供了有關市場驅動因素、限制因素、機會、新產品發布或批准、市場趨勢、區域前景以及主要參與者採用的競爭策略的重要見解。
根據公司亮點、產品組合、關鍵亮點、財務業績和戰略等參數對全球傷寒疫苗市場的主要參與者進行了分析。
本研究涵蓋的主要公司包括GlaxoSmithKline Plc., Sanofi SA, Bharat Biotech, Bio-Med Pvt. Ltd., PT Bio Farma, PaxVax, Inc. Shanghai Institute of Biological Products Co., Ltd., 和 Prokarium.
本報告中的見解將使營銷人員和公司高管能夠就未來的產品發布、類型升級、市場擴張和營銷策略做出明智的決策。
全球傷寒疫苗市場報告迎合了該行業的各種利益相關者，包括投資者、供應商、產品製造商、分銷商、新進入者和財務分析師。
利益相關者可以通過用於分析全球傷寒疫苗市場的各種戰略矩陣來促進他們的決策。

內容

第 1 章目的和先決條件

調查目的
先決條件
縮寫說明

第二章市場展望

舉報內容
- 市場定義和範圍
執行摘要
- 市場快照：按疫苗類型
- 按管理途徑劃分的市場概況
- 市場概況：按地區劃分
連貫的機會圖 (COM)

第 3 章市場動態、法規和趨勢分析

市場動態
- 驅動程序
- 限制因素
- 市場機會
影響分析
新產品發布/批准
PEST 分析
意識提升策略
保險報銷場景
傷寒疫苗短缺
臨床試驗分析
蛇咬傷事故多發的國家
市場進入挑戰

第 4 章全球傷寒疫苗市場 - 冠狀病毒 (COVID-19) 大流行的影響

整體影響
政府舉措
COVID-19 對市場的影響

第 5 章全球傷寒疫苗市場：按疫苗類型，2017-2030 年

減毒活疫苗
莢膜多醣疫苗
結合疫苗
其他

第 6 章按管理途徑分列的全球傷寒疫苗市場：2017-2030 年

口服給藥
父母

第 7 章全球傷寒疫苗市場：2017-2030 年各地區

北美
美國
加拿大
拉丁美洲
巴西
墨西哥
阿根廷
其他拉丁美洲地區
歐洲
英國
德國
意大利
法國
西班牙
俄羅斯
其他歐洲
亞太地區
中國
印度
日本
東盟
澳大利亞
韓國
其他亞太地區
中東
海合會
以色列
其他中東
非洲
北非
中非
南非

第 8 章競爭格局

熱圖分析
公司簡介
- GlaxoSmithKline Plc.
- Sanofi SA
- Bharat Biotech
- Bio-Med Pvt. Ltd.
- PT Bio Farma
- PaxVax, Inc.
- Shanghai Institute of Biological Products Co., Ltd.
- Prokarium

第九章章節

參考資料
調查方法

簡介目錄

Product Code: CMI2552

Typhoid fever is a bacterial infection caused by Salmonella typhi, which causes symptoms such as prolonged fever, headache, nausea, loss of appetite, and constipation or sometimes diarrhea. The bacterium usually enters the body through the mouth by the ingestion of contaminated food or water, penetrates the intestinal wall, and multiplies in lymphoid tissue. It then enters the bloodstream and causes bacteremia. People who drink contaminated water or eat food washed in contaminated water can develop typhoid fever. Typhoid fever is majorly caused in area with poor sanitation and lack of clean drinking water. Typhoid fever vaccines are the biological formulations, which provide immunity and protect an individual against typhoid fever.

Currently there are three typhoid vaccines recommended by the World Health organization (WHO) for use which include:

Injectable typhoid conjugate vaccine (TCV), consisting of Vi polysaccharide antigen linked to tetanus toxoid protein licensed for children from 6 months of age and adults up to 45 years of age
Injectable unconjugated polysaccharide vaccine based on the purified Vi antigen (known as Vi-PS vaccine) for persons aged two years and above, and
Oral live attenuated Ty21a vaccine in capsule formulation for those over six years of age

Market Dynamics

Increasing initiatives by governments and various other organizations to increase awareness about typhoid vaccine and rising access of new vaccines is expected to drive the typhoid fever vaccines market growth during forecast period. For instance, in February 2019, Gavi, the Vaccine Alliance in partnership with WHO, Center for Disease Control and Prevention and Zimbabwe's Ministry of Health launched a campaign to tackle typhoid outbreak in Zimbabwe. Gavi, the Vaccine Alliance is a public-private partnership that helps vaccinate half the world's children against some of the world's deadliest diseases. The campaign aims to vaccinate 325,000 people in nine suburbs of Zimbabwe's capital with new typhoid conjugate vaccine (TCV). At least 12.4 million children worldwide are categorized as 'zero-dose', living in missed communities that cannot access many essential services, including health care.

Key features of the study:

This report provides an in-depth analysis of the global typhoid fever vaccines market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global typhoid fever vaccines market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include GlaxoSmithKline Plc., Sanofi SA, Bharat Biotech, Bio-Med Pvt. Ltd., PT Bio Farma, PaxVax, Inc. Shanghai Institute of Biological Products Co., Ltd., and Prokarium.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global typhoid fever vaccines market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global typhoid fever vaccines market

Detailed Segmentation:

Global Typhoid Fever Vaccines Market, By Vaccine Type:
- Live Attenuated Vaccine
- Capsular Polysaccharide Vaccines
- Conjugate Vaccine
- Others
Global Typhoid Fever Vaccines Market, By Route of Administration:
- Oral
- Parenteral
Global Typhoid Fever Vaccines Market, By Region:
- North America
  - By Country
- U.S.
- Canada
- Latin America
  - By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
  - By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
  - By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
  - By Country
- GCC
- Israel
- Rest of Middle East
- Africa
  - By Region
- South Africa
- Central Africa
- North Africa
Company Profiles
- GlaxoSmithKline Plc.*
  - Company Highlights
  - Products Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Sanofi SA
- Bharat Biotech
- Bio-Med Pvt. Ltd.
- PT Bio Farma
- PaxVax, Inc.
- Shanghai Institute of Biological Products Co., Ltd.
- Prokarium

"*" marked represents similar segmentation in other categories in the respective section.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Vaccine Type
- Market Snapshot, By Route of Administration
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Novel Product Launch/Approval
PEST Analysis
Awareness Strategy
Reimbursement Scenario
Typhoid Fever Vaccines Shortage
Clinical Trial Analysis
Countries with High Number of Incidents of Snake Bites
Market Entry Challenges

4. Global Typhoid Fever Vaccines Market- Impact of Coronavirus (Covid-19) Pandemic

Overall Impact
Government Initiatives
COVID-19 Impact on the market

5. Global Typhoid Fever Vaccines Market, By Vaccine Type, 2017 - 2030, (US$ Million)

Overview
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
Live Attenuated Vaccine
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Capsular Polysaccharide Vaccines
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Conjugate Vaccine
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

6. Global Typhoid Fever Vaccines Market, By Route of Administration, 2017 - 2030, (US$ Million)

Overview
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
Oral
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Parental
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

7. Global Typhoid Fever Vaccines Market, By Region, 2017 - 2030, (US$ Million)

Introduction
- Market Share Analysis, By Region, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, For Regions, 2017-2030
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
U.S.
Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
Brazil
Mexico
Argentina
Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
GCC
Israel
Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2017 - 2030, (US$ Million)
North Africa
Central Africa
South Africa